bibliographic resource 8212789 [br/8212789]
https://w3id.org/oc/corpus/br/8212789
- is a
-
- title
-
- Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathwayâtargeted therapy and one prior mTOR inhibitor therapy.
- publication date
-
- contributor
-
- format
-
- identifier
-
- part of
-